Blueprint Medicines — Technical Presentation (June 2019)
18 slides from Blueprint Medicines's technical presentation, Jun 3, 2019
Slide 1: Clinical Activity and Tolerability of BLU-667 in RET-Fusion+ NSCLC
Clinical Activity and Tolerability of BLU-667, a Highly Potent and Selective RET Inhibitor, in Patients with Advanced RET-Fusion+ Non-small Cell Lung Cancer Justin F. Gainor1, Dae Ho Lee2, Giuseppe Curigliano3, Robert C. Doebele4, Dong-Wan Kim5, Christina S. Baik6, Daniel Shao-Weng Tan7, Gilberto Lo
Slide 2: Disclosures
Disclosures 2 Justin F. Gainor, MD • Honoraria: Pfizer, Novartis, Theravance, Merck, Incyte, Roche • Consulting or advisory role: Bristol-Myers Squibb, Ariad/Takeda, Genentech/Roche, Loxo, Blueprint Medicines, Amgen, Agios, Regeneron, Oncorus • Research funding: Novartis, Genentech, Takeda • Institu
Slide 3: RET Alterations: Diverse Oncogenic Drivers Lacking Targeted Therapeutic Approach
RET Alterations: Diverse Oncogenic Drivers Lacking Targeted Therapeutic Approach Justin F. Gainor 3 • Chemotherapy: nonspecific, low response rates, significant toxicity NSCLC patients with RET fusions have not significantly benefited from existing therapy Non-small cell lung cancer: ~1-2% RET fusio
Slide 4: Potently and Selectively Inhibits RET Alterations and Resistance Mutants
BLU-667 Potently and Selectively Inhibits RET Alterations and Resistance Mutants Justin F. Gainor 4 aKinome illustration reproduced courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com) (CSTI). The foregoing website is maintained by CSTI, and Blueprint Medicines is not responsible for its
Slide 5: ARROW: BLU-667 Dose-Escalation and Expansion Study
ARROW: BLU-667 Dose-Escalation and Expansion Study ARROW is registered with clinicaltrials.gov (NCT03037385) Part 1: Dose-Escalation (N=62; Complete)1 Phase 2 dose determined (400 mg QD) Justin F. Gainor 5 BID, twice daily dosing; ECOG PS, Eastern Cooperative Oncology Group performance status; MTC,
Slide 6: Baseline Characteristics RET Fusion+ Advanced NSCLC Patients
Baseline Characteristics RET Fusion+ Advanced NSCLC Patients ECOG PS, Eastern Cooperative Oncology Group Performance Status. aSmoking history is unknown for one patient. bIncludes RET fusion+ by fluorescence in situ hybridization (FISH); RET fusion partner to be determined via central analysis. Data
Slide 7: BLU-667 is Well Tolerated by Patients with RET Fusion+ Advanced NSCLC
BLU-667 is Well Tolerated by Patients with RET Fusion+ Advanced NSCLC RET Fusion+ Advanced NSCLC 400 mg QD Starting Dose (N=120) Adverse Events Treatment-Emergent (≥15% overall) Treatment-Related All Grade ≥3 All Grade ≥3 Constipation 30% 2% 17% 2% Neutropeniaa 26% 13% 26% 13% AST increased 24% 5% 2
Slide 8: BLU-667 Demonstrates Substantial Antitumor Activity in RET Fusion+ Advanced NSCLC
BLU-667 Demonstrates Substantial Antitumor Activity in RET Fusion+ Advanced NSCLC 8 CI, confidence interval; CR, complete response; DCR, disease control rate (best response of SD or better); ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease. Patients enrol
Slide 9: BLU-667 Induces Rapid and Durable Responses in RET Fusion+ Advanced NSCLC
0 2 4 6 8 10 12 14 16 Treatment Duration (Months) BLU-667 Induces Rapid and Durable Responses in RET Fusion+ Advanced NSCLC 9 Justin F. Gainor Patients enrolled by 14 Nov 18, data cut-off 28 Apr 19. Treatment ongoing Treatment after PD Post-treatment follow-up CR PR PD - Most responses occur at the
Slide 10: BLU-667 is Active Regardless of Prior Checkpoint Treatment
BLU-667 is Active Regardless of Prior Checkpoint Treatment Justin F. Gainor -100 -80 -60 -40 -20 0 20 40 Maximum Reduction - Sum of Diameter Change from Baseline, % BLU-667 Starting Dose 400 mg QD 10 Patients enrolled by 14 Nov 18, data cut-off 28 Apr 19. -100 -80 -60 -40 -20 0 20 40 Maximum % Reduc
Slide 11: BLU-667 is Active Across RET Fusion Genotypes
BLU-667 is Active Across RET Fusion Genotypes Justin F. Gainor -100 -80 -60 -40 -20 0 20 40 Maximum % Reduction from Baseline Sum of Diameters of Target Lesions BLU-667 Starting Dose 400 mg QD CCDC6 KIF5B Other/unknown 11 Patients enrolled by 14 Nov 18, data cut-off 28 Apr 19.
Slide 12: BLU-667 is Active Regardless of CNS Involvement
BLU-667 is Active Regardless of CNS Involvement Justin F. Gainor -100 -80 -60 -40 -20 0 20 40 Maximum % Reduction from Baseline Sum of Diameters of Target Lesions BLU-667 Starting Dose 400 mg QD CNS involvement No CNS involvement 12 CNS, central nervous system Patients enrolled by 14 Nov 18, data cu
Slide 13: BLU-667 is Active Against Intracranial Metastases
BLU-667 is Active Against Intracranial Metastases • 7 of 9 (78%) patients had shrinkage of measurable brain metastases • No patients at 400 mg QD starting dose had progression due to new CNS involvement Justin F. Gainor 13 aData shown for 9 patients with brain lesion(s) identified as RECIST 1.1 targ
Slide 14: BLU-667 is Active Against Intracranial Metastases
• 52-year-old woman, RET fusion+ NSCLC, prior platinum and checkpoint inhibitor • Near-complete resolution of previously untreated target brain metastasis after two months of BLU-667 400 mg QD • Continues to receive treatment with ongoing confirmed PR (70% shrinkage) at 6 months • 59-year-old man,
Slide 15: Rapid and Robust Clearance of RET Variant ctDNA with BLU-667
Rapid and Robust Clearance of RET Variant ctDNA with BLU-667 Among patients receiving a BLU-667 starting dose of 400 mg QD: • 18/20 (90%) with detectable RET fusion ctDNA at baseline had complete clearance within the first cycle • Clearance of genomic driver variants ctDNA has been associated with i
Slide 16: BLU-667 has Activity in Other RET Fusion+ Malignancies
BLU-667 has Activity in Other RET Fusion+ Malignancies • PR in 2/2 patients with metastatic pancreatic cancer - 67 yo male, CCDC6-RET fusion, continues with confirmed PR (53% shrinkage) at 6 months – 31 yo male, TRIM33-RET and JMJD1C-RET fusions, continues treatment after PR (41% shrinkage) at firs
Slide 17: Conclusions
Conclusions • BLU-667 demonstrates broad and durable antitumor activity in patients with RET fusion+ advanced NSCLC - 60% ORR and 100% DCR in patients previously treated with platinum chemotherapy, and 58% ORR in all RET fusion+ patients - Responses observed regardless of treatment history, RET fusi
Slide 18: Acknowledgments
Acknowledgments • Participating patients and families • BLU-667-1101 Investigators and research coordinators • Colleagues at Blueprint Medicines Corporation 18 Justin F. Gainor - The University of Texas MD Anderson Cancer Center, Houston, TX, United States - Oregon Health & Science University, Portl
Blueprint Medicines — Technical Presentation (June 2019) on 6ix